Drug combinations with proteasome inhibitors in antitumor therapy

Area of Science:

• Oncology
• Molecular Biology
• Pharmacology

Background:

• The proteasome is a validated target for antitumor therapy, particularly in multiple myeloma.
• Proteasome inhibitors show potential in combination with other anticancer agents.
• Synergistic effects have been observed in preclinical studies for both hematological and solid tumors.

Purpose of the Study:

• To explore the efficacy of proteasome inhibitors in combination with conventional and targeted antitumor agents.
• To elucidate the mechanistic basis for enhanced drug efficacy in combined treatment strategies.
• To review current clinical investigations and future directions in proteasome inhibitor-based combination therapies.

Main Methods:

• Review of preclinical cellular studies investigating drug interactions.
• Analysis of mechanistic data on proteasome inhibitor effects on drug targets and cellular pathways.
• Summary of ongoing clinical trials evaluating combination therapies.

Main Results:

• Proteasome inhibitors demonstrate synergistic effects when combined with cytotoxic agents (e.g., topoisomerase inhibitors) and targeted agents (e.g., histone deacetylase inhibitors).
• Mechanisms include interference with the stability of cytotoxic drug targets and modulation of cellular protective pathways like DNA repair and NF-kB signaling.
• Synergy with targeted agents involves complex interactions dependent on the specific drug and its target.

Conclusions:

• Combination therapy involving proteasome inhibitors offers a promising strategy to enhance antitumor treatment efficacy.
• Further clinical studies are crucial to optimize these combination approaches for various cancer types.
• Ongoing research in proteasome inhibition is expected to significantly advance our understanding of tumor response to treatment.